ImageneBio (IMA) EBIT Margin (2020 - 2025)

ImageneBio (IMA) posted EBIT Margin of 749.38% for Q1 2025, down 1188.22% sequentially from 58.17% in Q3 2024.

ImageneBio (IMA) EBIT Margin (2020 - 2025) Analysis & Trends

ImageneBio has reported EBIT Margin for 6 years, with the latest figure at 749.38% in Q1 2025.

Quarterly EBIT Margin changed N/A year-over-year to 749.38% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 845.85% (changed N/A YoY) and the FY2023 annual result came in at 823.33%, down 36934.0% from the prior year.
EBIT Margin fell to 749.38% in Q1 2025 per IMA's latest filing, from 58.17% in the prior quarter.
Over five years, EBIT Margin peaked at 13.81% in Q4 2021 and troughed at 5484.55% in Q2 2022.
A 5-year average of 1039.0% and a median of 372.57% in 2021 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2021 and 2022: EBIT Margin surged 4009535 bps in 2021, then slumped 512707 bps in 2022.
Over 5 years, EBIT Margin stood at 13.81% in 2021, then sank by 2108 bps to 277.32% in 2022, then tumbled by 1099 bps to 3324.43% in 2023, then jumped by 98 bps to 58.17% in 2024, then slumped by 1188 bps to 749.38% in 2025.
According to Business Quant data, EBIT Margin over the past three periods registered 749.38%, 58.17%, and 3324.43% for Q1 2025, Q3 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	138.53 Bn	130.68 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.34 Bn	78.35 Bn	3.93 Bn	30.15%
3	Argenx Se	64.67 Bn	59.48 Bn	1.37 Bn	32.54%
4	Moderna	59.04 Bn	53.90 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.03 Bn	36.94 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.78 Bn	27.47 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.81 Bn	9.42 Bn	668.28 Mn	-35.57%
8	Insmed	27.21 Bn	26.05 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	26.99 Bn	26.15 Bn	-	19.75%
10	ImageneBio	49.67 Mn	-85.68 Mn	-	-

Download Data